Quantcast
Last updated on April 24, 2014 at 10:35 EDT

Latest Novator Partners Stories

2012-04-25 10:25:31

PARSIPPANY, N.J., April 25, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Actavis Group today jointly announced that Watson has entered into a definitive agreement to acquire privately held Actavis for an upfront payment of EUR4.25 billion. As a result of this acquisition, Watson will become the third largest global generics company with 2012 anticipated pro forma revenue of approximately $8 billion. To view the multimedia assets associated with this release, please...

2012-04-25 10:25:07

PARSIPPANY, N.J., April 25, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Actavis Group today jointly announced that Watson has entered into a definitive agreement to acquire privately held Actavis for an upfront payment of EUR4.25 billion. As a result of this acquisition, Watson will become the third largest global generics company with 2012 anticipated pro forma revenue of approximately $8 billion. Actavis, which as a stand-alone company was positioned for strong...

2011-12-21 06:00:00

MORRISTOWN, N.J., Dec. 21, 2011 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that its US subsidiary, Actavis Inc, has entered into a binding letter of intent (LOI) with QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) to commercialize MoxDuo IR in the United States. Under the terms of the LOI, Actavis gets exclusive rights to launch and market MoxDuo IR, a patented 3:2 ratio fixed dose combination of morphine and oxycodone...